-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Akumin (NASDAQ:AKU) & Sera Prognostics (NASDAQ:SERA) Critical Survey
Akumin (NASDAQ:AKU) & Sera Prognostics (NASDAQ:SERA) Critical Survey
Akumin (NASDAQ:AKU – Get Rating) and Sera Prognostics (NASDAQ:SERA – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Insider and Institutional Ownership
25.8% of Akumin shares are owned by institutional investors. Comparatively, 31.3% of Sera Prognostics shares are owned by institutional investors. 11.6% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Get Akumin alerts:Earnings and Valuation
This table compares Akumin and Sera Prognostics' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Akumin | $421.08 million | 0.16 | -$43.29 million | ($1.65) | -0.44 |
Sera Prognostics | $80,000.00 | 620.34 | -$35.01 million | ($1.53) | -1.05 |
Analyst Recommendations
This is a breakdown of current recommendations for Akumin and Sera Prognostics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Akumin | 2 | 0 | 0 | 0 | 1.00 |
Sera Prognostics | 0 | 1 | 3 | 0 | 2.75 |
Akumin presently has a consensus price target of $0.63, suggesting a potential downside of 14.38%. Sera Prognostics has a consensus price target of $6.25, suggesting a potential upside of 290.63%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Akumin.
Risk & Volatility
Akumin has a beta of -0.7, meaning that its share price is 170% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Profitability
This table compares Akumin and Sera Prognostics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Akumin | -19.73% | -46.21% | -5.68% |
Sera Prognostics | -20,490.83% | -38.32% | -35.85% |
Summary
Sera Prognostics beats Akumin on 10 of the 14 factors compared between the two stocks.
About Akumin
(Get Rating)
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
About Sera Prognostics
(Get Rating)
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.
Akumin (NASDAQ:AKU – Get Rating) and Sera Prognostics (NASDAQ:SERA – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
纳斯达克:AKU-GET)和SERA预见者(纳斯达克:SERA-GET评级)都是小盘医疗公司,但哪一家更好?我们将根据分析师建议的力度、盈利能力、估值、机构所有权、股息、风险和收益对这两家公司进行对比。
Insider and Institutional Ownership
内部人与机构持股
25.8% of Akumin shares are owned by institutional investors. Comparatively, 31.3% of Sera Prognostics shares are owned by institutional investors. 11.6% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Akumin的25.8%股份由机构投资者持有。相比之下,Sera Prognostics 31.3%的股份由机构投资者持有。Sera Prognostics 11.6%的股份由内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金经理相信,从长期来看,一只股票的表现将好于大盘。
Earnings and Valuation
收益和估值
This table compares Akumin and Sera Prognostics' revenue, earnings per share and valuation.
该表比较了Akumin和Sera Prognostics的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Akumin | $421.08 million | 0.16 | -$43.29 million | ($1.65) | -0.44 |
Sera Prognostics | $80,000.00 | 620.34 | -$35.01 million | ($1.53) | -1.05 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
阿库明 | 4.2108亿美元 | 0.16 | -4,329万元 | ($1.65) | -0.44 |
血清预测者 | $80,000.00 | 620.34 | -3,501万元 | ($1.53) | -1.05 |
Analyst Recommendations
分析师建议
This is a breakdown of current recommendations for Akumin and Sera Prognostics, as provided by MarketBeat.com.
这是MarketBeat.com提供的对Akumin和Sera Prognostics的当前建议的细分。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Akumin | 2 | 0 | 0 | 0 | 1.00 |
Sera Prognostics | 0 | 1 | 3 | 0 | 2.75 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
阿库明 | 2 | 0 | 0 | 0 | 1.00 |
血清预测者 | 0 | 1 | 3 | 0 | 2.75 |
Akumin presently has a consensus price target of $0.63, suggesting a potential downside of 14.38%. Sera Prognostics has a consensus price target of $6.25, suggesting a potential upside of 290.63%. Given Sera Prognostics' stronger consensus rating and higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Akumin.
Akumin目前的普遍目标价为0.63美元,这意味着潜在的下行幅度为14.38%。Sera Prognostics的共识目标价为6.25美元,暗示潜在上涨290.63%。考虑到Sera Prognostics的更高共识评级和更高的可能上行空间,分析师显然认为Sera Prognostics比Akumin更有利。
Risk & Volatility
风险与波动性
Akumin has a beta of -0.7, meaning that its share price is 170% less volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Akumin的贝塔系数为-0.7,这意味着其股价的波动性比标准普尔500指数低170%。相比之下,Sera Prognostics的贝塔系数为0.58,这意味着其股价的波动性比标准普尔500指数低42%。
Profitability
盈利能力
This table compares Akumin and Sera Prognostics' net margins, return on equity and return on assets.
下表比较了Akumin和Sera Prognostics的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Akumin | -19.73% | -46.21% | -5.68% |
Sera Prognostics | -20,490.83% | -38.32% | -35.85% |
净利润率 | 股本回报率 | 资产回报率 | |
阿库明 | -19.73% | -46.21% | -5.68% |
血清预测者 | -20,490.83% | -38.32% | -35.85% |
Summary
摘要
Sera Prognostics beats Akumin on 10 of the 14 factors compared between the two stocks.
Sera Prognostics在两只股票之间进行比较的14个因素中,有10个超过了Akumin。
About Akumin
关于Akumin
(Get Rating)
(获取评级)
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
Akumin Inc.在美国提供门诊诊断成像服务。它分为两个部门,放射科和肿瘤科。该公司提供各种医疗成像服务,包括磁共振成像、计算机断层扫描、正电子发射断层扫描、核医学、乳房X光照相、超声波、数字放射照相、透视和其他诊断或介入放射学程序,该网络由大约200个拥有和/或运营的成像地点组成。它为46个州的大约1,000家医院和卫生系统提供门诊放射学和肿瘤学服务和解决方案。Akumin Inc.成立于2015年,总部位于佛罗里达州普兰特。
About Sera Prognostics
关于SERA预测学
(Get Rating)
(获取评级)
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics,Inc.,一家妇女健康诊断公司,发现、开发并商业化用于改善妊娠结局的生物标记物测试。该公司开发了PreTRM测试,这是一种基于血液的生物标志物测试,用于预测无症状单胎妊娠的自发早产风险。该公司还在开发各种妊娠相关疾病的候选产品组合,包括先兆子痫、分子出生时间、妊娠期糖尿病、胎儿生长受限、死产和产后抑郁症。该公司成立于2008年,总部设在犹他州盐湖城。
Receive News & Ratings for Akumin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akumin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Akumin Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Akumin和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧